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Introduction
The optimal duration of anticoagulation in patients with unprovoked venous thromboembolism (VTE) is controversial. In these patients, the risk of recurrent events during the first year after anticoagulation is discontinued is between 5% and 10% [1] . The American College of Chest Physicians recommends a minimum of 3 months of anticoagulation therapy and to consider prolonged treatment in patients with low or moderate risk of major bleeding events [1] . To counsel patients, clinicians need accurate estimates of the risks of recurrent VTE and of major bleeding episodes with different therapeutic strategies to ensure that the benefits outweigh the risks of long-term secondary prevention. The risk of major bleeding after completing anticoagulant therapy is unknown in this patient population. Therefore, the incremental risks of major bleeding with various treatment strategies over and above the risk with no anticoagulant therapy are unclear. This systematic review and meta-analysis evaluates the rate of major bleeding episodes in high-risk patients participating in trials for the secondary prevention of recurrent VTE who received placebo or observation only (i.e. no anticoagulant therapy).
and acenocoumarol. The following terms were also added to the search strategy: recurrent venous thromboembolism, oral anticoagulants, dabigatran, rivaroxaban, apixaban, and ximelagatran. The outcomes were major bleeding and fatal bleeding as defined by ISTH [2] or per individual study. The methodological quality was evaluated using the Risk of Bias Assessment Tool from the Cochrane Handbook for randomized trials [3] . The primary measurement was bleeding event rates reported per 100 patient-years stratified according to the underlying treatment strategy with its associated 95% CIs. Pooled measurements were calculated using a random-effects model within the Stats Direct software (version 2.7.9; StatsDirect Ltd, Cheshire, UK). Heterogeneity was assessed using the I 2 test [4] .
Results and discussion
Our systematic search identified 636 citations. A total of 11 trials assessing anticoagulation for secondary prevention after VTE were included in the analysis [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Eight studies were randomized placebo-controlled trials [5] [6] [7] [8] [9] 11, 12, 14] , two studies compared vitamin K antagonist (VKA) treatment with observation [13, 15] , and one study compared different durations of VKA therapy (the period of observation for major bleeding and fatal bleeding events after completing a fixed duration of anticoagulation was included in this analysis) [9, 10] . All studies were judged to be at low risk of bias according to the risk of bias assessment tool. A total of 3965 patients were included in our analysis; 3630 were treated with placebo and 335 patients were simply observed for bleeding events ( Table 1 ). The total population was followed for a median of 23.9 months (range 6-40.3 months); the median follow-up for those receiving placebo was 14.3 months (6-25.2 months) and 37.2 months for those enrolled in observation without anticoagulation only arms (32.7-40.3 months). The majority of patients were male (median 57%, range 51%-63%); the mean age varied between 53 and 68 years; and most patients had unprovoked VTE (median 100%, range 57%-100%).
The overall pooled major bleeding rate in patients who have completed anticoagulation for the secondary prevention of recurrent VTE (i.e. no longer on anticoagulant therapy) was 0.45 per 100 patient-years (95% CI 0.29-0.64, I 2 = 0%). The pooled major bleeding rate for patients randomized to placebo was 0.42 per 100 patientyears (95% CI 0.25-0.62, I 2 = 0%), and that for patients randomized to observation was 0.62 per 100 patient-years (95% CI 0.23-1.2, I 2 = 0%) (Fig. 1) . Fatal bleeding events were rare with an overall pooled fatal bleeding rate of 0.14 per 100 patient-years (95% CI 0.057-0.26, I 2 = 0%). In the studies reporting sites of major bleeding and fatal bleeding, intracranial hemorrhage (including subdural and subarachnoid bleeding) and gastrointestinal bleeding were most common.
Our systematic review demonstrates that patients not receiving anticoagulant or antiplatelet therapy for the secondary prevention of recurrent VTE also experience major bleeding events. This event rate needs to be accounted for and included in the risk-benefit ratio, along with the previously reported risk of recurrent VTE, on and off anticoagulation, and risk of major bleeding on anticoagulant therapy, when clinicians are deciding on the length of anticoagulation therapy for patients with unprovoked VTE [16] [17] [18] [19] [20] .
The rate of major bleeding events for patients with VTE on oral anticoagulation has previously been reported to be approximately 2.1 per 100 patient-years (95% CI 1.6-2.6) [17] . [20] . In that review, the new oral anticoagulant apixaban, at two different treatment doses, was associated with the lowest risk of major bleeding events relative to placebo or observation.
It is interesting to note that the rates of major bleeding are higher in patients randomized to observation than those on placebo, although this finding is not significant. This may be attributed to different definitions of major bleeding used among the trials. All three trials randomizing patients to observation were published between 1997 and 2003-that is, before the ISTH criteria were established.
Our review has several strengths and limitations. First, all bleeding events were independently adjudicated; second, there was no heterogeneity identified between studies. Limitations of this study include the relatively small sample size of patients randomized to observation and generalizability to clinical practice. With respect to this latter concern, the patient population was extracted from RCTs. These patients are selected for participation, are likely younger, and generally do not have a history of bleeding events and severe comorbidities as they are often excluded from such studies, which may underestimate the true "real-world" bleeding risk and make our reported rate a conservative estimate. Timing of major bleeding events and known risk factors for major bleeding (antiplatelet use, moderate renal dysfunction, active malignancy, etc.) were not consistently reported in all trials, and therefore subgroup analyses could not be conducted. Last, observational prospective cohort studies were not included in the review. Although this could provide more insight into "real-world" bleeding risks, it may have significantly increased heterogeneity given the potential lack of independent adjudication or the use of standardized definitions of major bleeding.
In conclusion, our review suggests that the incidence of major bleeding events is non-negligible in patients receiving no treatment and may change the estimate of the incremental harm-benefit ratio clinicians consider when discussing anticoagulation for secondary prevention of recurrent VTE with patients.
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